A Phase 3 interventional study of tadalafil and placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 21 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 27th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 19 in phase 3, and was the 23rd registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 22nd largest by enrollment, is one of 4 that started in 2009, is one of 13 in phase 3, and was the 18th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: tadalafil
Drug: placebo
5 milligrams (mg) administered orally once a day for 12 weeks
Also known as: Cialis, LY450190
tablet administered orally once a day for 12 weeks.
Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12
Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.
Time frame: Baseline, Week 12
Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per participant.
Time frame: Baseline, Week 12
Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary
The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.
Time frame: Baseline, 12 weeks
The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint
The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).
Time frame: Week 12
Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire
SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
Time frame: Baseline, Week 12
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of "Yes" Responses
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. "Were you able to achieve at least some erection (some enlargement of the penis)? " Data are presented as the mean percentage of yes responses per participant.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of "Yes" Responses
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per participant.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of "Yes" Responses
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per participant.
Time frame: Baseline, 12 weeks
Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.
Time frame: Week 12
Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.
Time frame: Week 12
| Milestone | Tadalafil | Placebo |
|---|---|---|
| Started | 147 | 70 |
| Completed | 130 | 64 |
| Not completed | 17 | 6 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 9 | 4 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Baseline | 15.5 ± 6.00 | 16.0 ± 6.27 |
| Week 12 Change | 7.3 ± 6.01 | 3.3 ± 5.98 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per participant.
| percentage of yes responses | Tadalafil | Placebo |
|---|---|---|
| Baseline | 60.1 ± 38.77 | 59.9 ± 38.83 |
| Week 12 Change | 23.2 ± 31.92 | 11.6 ± 25.48 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant.
| percentage of yes responses | Tadalafil | Placebo |
|---|---|---|
| Baseline | 28.2 ± 31.86 | 32.2 ± 35.93 |
| Week 12 Change | 39.4 ± 34.71 | 19.3 ± 36.18 |
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded.
| Number of events per night | Tadalafil | Placebo |
|---|---|---|
| Baseline (n=122, n=63) | 2.75 ± 2.270 | 2.44 ± 2.002 |
| Week 12 Change (n=96, n=49) | -0.11 ± 2.592 | -0.09 ± 2.214 |
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12.
| minutes | Tadalafil | Placebo |
|---|---|---|
| Baseline (n=104, n=56) | 28.487 ± 14.4791 | 26.372 ± 11.8969 |
| Week 12 Change (n=65, n=33) | -1.553 ± 16.0073 | -0.398 ± 12.4585 |
NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12.
| percent of volumetric change | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change | -5.96 ± 74.647 | -50.30 ± 150.321 |
The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.
| percent | Tadalafil | Placebo |
|---|---|---|
| Baseline (n=145, n=67) | 31.0 ± 27.21 | 28.9 ± 25.74 |
| Week 12 Change (n=145, n=66) | 27.5 ± 25.29 | 11.9 ± 22.00 |
The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint | 72.8 ± 20.66 | 52.7 ± 22.62 |
SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Total (Baseline) | 47.3 ± 21.95 | 47.9 ± 21.58 |
| Total (Change) | 20.4 ± 23.85 | 8.3 ± 21.14 |
| Sexual Relationship Domain (Baseline) | 43.0 ± 22.54 | 43.9 ± 21.68 |
| Sexual Relationship Domain (Change) | 23.4 ± 25.88 | 9.7 ± 22.35 |
| Confidence Domain (Baseline) | 53.1 ± 25.58 | 53.1 ± 24.85 |
| Confidence Domain (Change) | 16.5 ± 25.58 | 6.5 ± 24.57 |
| Self-Esteem Domain (Baseline) | 50.5 ± 28.15 | 48.5 ± 30.06 |
| Self-Esteem Domain (Change) | 19.2 ± 27.85 | 9.3 ± 30.05 |
| Overall Relationship Domain (Baseline) | 58.2 ± 31.47 | 62.3 ± 29.01 |
| Overall Relationship Domain (Change) | 11.0 ± 32.51 | 0.9 ± 30.17 |
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Baseline | 6.5 ± 2.99 | 7.2 ± 2.81 |
| Week 12 Change | 2.0 ± 2.78 | 0.5 ± 2.02 |
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Baseline | 6.7 ± 1.81 | 6.6 ± 1.87 |
| Week 12 Change | 0.5 ± 1.93 | -0.1 ± 1.78 |
Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Baseline | 8.2 ± 2.65 | 7.6 ± 2.43 |
| Week 12 Change | 2.1 ± 2.67 | 1.5 ± 2.56 |
Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.
| units on a scale | Tadalafil | Placebo |
|---|---|---|
| Baseline | 5.2 ± 2.15 | 5.1 ± 2.11 |
| Week 12 Change | 2.0 ± 2.37 | 0.8 ± 2.19 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. "Were you able to achieve at least some erection (some enlargement of the penis)? " Data are presented as the mean percentage of yes responses per participant.
| percentage of yes responses | Tadalafil | Placebo |
|---|---|---|
| Baseline | 80.8 ± 28.52 | 74.2 ± 34.26 |
| Week 12 Change | 12.5 ± 24.03 | 9.5 ± 24.67 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per participant.
| percentage of yes responses | Tadalafil | Placebo |
|---|---|---|
| Baseline | 11.7 ± 21.16 | 14.6 ± 23.30 |
| Week 12 Change | 44.1 ± 35.75 | 18.3 ± 32.14 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per participant.
| percentage of yes responses | Tadalafil | Placebo |
|---|---|---|
| Baseline | 10.3 ± 20.36 | 12.9 ± 22.11 |
| Week 12 Change | 43.2 ± 35.52 | 18.5 ± 30.98 |
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.
| participants | Tadalafil | Placebo |
|---|---|---|
| Very Much Better | 49 ± 33.6 | 7 ± 10.1 |
| Much Better | 41 ± 28.1 | 8 ± 11.6 |
| Little Better | 29 ± 19.9 | 19 ± 27.5 |
| No Change | 14 ± 9.6 | 24 ± 34.8 |
| A Little Worse | 5 ± 3.4 | 5 ± 7.2 |
| Much Worse | 4 ± 1.4 | 3 ± 4.3 |
| Very Much Worse | 2 ± 1.4 | 1 ± 1.4 |
| Missing | 4 ± 2.7 | 2 ± 2.9 |
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.
| participants | Tadalafil | Placebo |
|---|---|---|
| Very Much Better | 40 ± 27.4 | 5 ± 7.2 |
| Much Better | 49 ± 33.6 | 11 ± 15.9 |
| Little Better | 28 ± 19.2 | 17 ± 24.6 |
| No Change | 17 ± 11.6 | 27 ± 39.1 |
| A Little Worse | 3 ± 2.1 | 4 ± 5.8 |
| Much Worse | 4 | 3 |
| Very Much Worse | 1 ± 0.7 | 0 ± 0 |
| Missing | 4 ± 2.7 | 2 ± 2.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil | — | 2/147 (1.4%) | 27/147 (18.4%) |
| Placebo | — | 1/70 (1.4%) | 7/70 (10%) |
| Event | Tadalafil | Placebo |
|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/147 | 1/70 |
| Tibia fractureInjury, poisoning and procedural complications | 0/147 | 1/70 |
| Rib fractureInjury, poisoning and procedural complications | 1/147 | 0/70 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/147 | 0/70 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 1/147 | 0/70 |
| Event | Tadalafil | Placebo |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 5/147 | 1/70 |
| NasopharyngitisInfections and infestations | 4/147 | 2/70 |
| DyspepsiaGastrointestinal disorders | 4/147 | 0/70 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/147 | 0/70 |
| HeadacheNervous system disorders | 4/147 | 0/70 |
| InfluenzaInfections and infestations | 0/147 | 1/70 |
| PharyngitisInfections and infestations | 0/147 | 1/70 |
| FallInjury, poisoning and procedural complications | 1/147 | 1/70 |
| Dysthymic disorderPsychiatric disorders | 0/147 | 1/70 |
| Maxillary antrum operationSurgical and medical procedures | 0/147 | 1/70 |
| Age Continuous(years) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 52.2 ± 10.90 | 51.9 ± 10.35 | 52.1 ± 10.71 |
| Sex: Female, Male(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 147 | 70 | 217 |
| Race/Ethnicity, Customized(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| White | 144 | 69 | 213 |
| Asian | 2 | 0 | 2 |
| Unknown | 1 | 1 | 2 |
| Region of Enrollment(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Germany | 39 | 19 | 58 |
| Greece | 19 | 9 | 28 |
| Italy | 27 | 13 | 40 |
| Poland | 31 | 14 | 45 |
| Spain | 31 | 15 | 46 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m²)) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 27.92 ± 4.685 | 27.74 ± 3.423 | 27.86 ± 4.313 |
The record gives a start of Jan 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil